Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation.

@article{Rosenberg2005InductionTW,
  title={Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation.},
  author={Paul B Rosenberg and Ank E Vriesendorp and Mark H. Drazner and Daniel L. Dries and Patricia A. Kaiser and Linda S. Hynan and J. Michael DiMaio and Daniel Meyer and William Steves Ring and Clyde W. Yancy},
  journal={The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation},
  year={2005},
  volume={24 9},
  pages={
          1327-31
        }
}
BACKGROUND Cyclosporine (CsA) is frequently initiated as induction therapy in patients undergoing orthotopic heart transplantation, but our experience has identified a significant rate of post-operative renal dysfunction. We therefore devised a renal-sparing cyclosporine-free induction regimen consisting of the early administration basiliximab, an interleukin-2 receptor monoclonal antibody, followed by the late initiation of cyclosporine on post-operative Day 4. METHODS Between September 1998… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 28 CITATIONS

Similar Papers

Loading similar papers…